ARQT
Arcutis Biotherapeutics, Inc.
NMS
$24.38
-0.21
(-0.85%)
Extended · +1.97σ
Grade B
Price chart
Overlay:
Click earnings ▲ markers for day-move details
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.1B | $-0.0B | $-0.0B | $0.0B | -10.7% | -8.6% |
| 2025-12-31 | $0.1B | $0.0B | $0.0B | $0.0B | 13.4% | 14.2% |
| 2025-09-30 | $0.1B | $0.0B | $0.0B | $-0.0B | 7.5% | 8.6% |
| 2025-06-30 | $0.1B | $-0.0B | $-0.0B | $-0.0B | -19.5% | -17.9% |
| 2025-03-31 | $0.1B | $-0.0B | $-0.0B | $-0.0B | -38.1% | -37.3% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-05-06 | -0.09 | -0.06 | -55.2% |
| 2026-02-25 | 0.13 | 0.09 | +46.8% |
| 2025-10-28 | 0.06 | -0.09 | +163.6% |
| 2025-08-06 | -0.13 | -0.16 | +17.9% |
| 2025-05-06 | -0.20 | -0.21 | +4.8% |
| 2025-02-25 | -0.09 | -0.26 | +66.0% |
| 2024-11-06 | -0.33 | -0.42 | +22.4% |
| 2024-08-14 | -0.42 | -0.53 | +20.8% |
| 2024-05-14 | -0.32 | -0.73 | +56.2% |
| 2024-02-27 | -0.72 | -0.80 | +10.0% |
| 2023-11-03 | -0.73 | -0.91 | +20.1% |
| 2023-08-08 | -1.16 | -1.25 | +7.0% |
| 2023-05-09 | -1.31 | -1.26 | -3.6% |
| 2023-02-28 | -1.18 | -1.44 | +17.8% |
| 2022-11-08 | -1.89 | -1.75 | -7.8% |
| 2022-08-04 | -1.31 | -1.42 | +7.8% |
| 2022-05-05 | -1.27 | -1.52 | +16.6% |
| 2022-02-22 | -1.42 | -1.54 | +7.9% |
| 2021-11-04 | -1.14 | -1.19 | +4.4% |
| 2021-08-05 | -0.84 | -0.93 | +9.3% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ARQT ★ | $3B | — | 21.1 | 7.3 | 538.2 | 16.1 | 90.9% | 60.1% | — | 0.12% |
| LLY | $1,010B | 40.3 | 25.5 | 14.0 | 28.9 | 32.4 | 82.8% | 55.5% | 169.9% | 0.91% |
| UNH | $371B | 30.8 | 19.5 | 0.8 | 19.8 | 3.8 | 18.8% | 2.0% | 0.7% | 4.77% |
| JNJ | $580B | 27.9 | 18.9 | 6.0 | 17.9 | 7.1 | 68.0% | 9.9% | -52.9% | 2.16% |
| MRK | $294B | 33.5 | 12.4 | 4.5 | 11.4 | 6.4 | 76.7% | 4.9% | — | 4.78% |
| ABBV | $402B | 111.1 | 14.0 | 6.4 | 15.6 | -60.5 | 72.0% | 12.4% | -46.2% | 5.17% |
| PFE | $149B | 20.0 | 9.3 | 2.4 | 7.9 | 1.7 | 74.8% | 5.4% | -10.1% | 8.29% |
| TMO | $174B | 25.8 | 17.2 | 3.9 | 19.0 | 3.3 | 40.9% | 6.2% | 11.3% | 3.17% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 55.96%
| Holder | Shares | % out |
|---|---|---|
| Suvretta Capital Management, LLC | 12,327,000 | 9.86% |
| Frazier Life Sciences Management, L. | 9,874,511 | 7.89% |
| Blackrock Inc. | 9,200,411 | 7.36% |
| Rubric Capital Management LP | 8,271,577 | 6.61% |
| State Street Corporation | 6,296,197 | 5.03% |
| Polar Capital Holdings PLC | 5,666,940 | 4.53% |
| Jennison Associates LLC | 4,980,770 | 3.98% |
| Vanguard Capital Management LLC | 4,871,536 | 3.89% |
| Gilder Gagnon Howe & Co LLC | 4,304,010 | 3.44% |
| Morgan Stanley | 4,218,931 | 3.37% |
Insider activity · 90d
15 buys / 0 sells · ratio 15.0 · Finnhub
- LIN SUE-JEAN BUY 16,667
- LIN SUE-JEAN BUY 32,513
- Welgus Howard G. BUY 16,667
- Welgus Howard G. BUY 38,378
- Krishnamohan Neha BUY 16,667
- Krishnamohan Neha BUY 27,901
- Curran Terrie BUY 16,667
- Curran Terrie BUY 23,526
- Munshi Amit BUY 16,667
- Munshi Amit BUY 9,799
Analyst estimates
FinnhubLow
$33.0
Mean
$34.625
High
$36.0
Analysts
8
Recommendation distribution · period 2026-06-01
4
8
2
Revision trend (2026-03-01 → 2026-06-01):
net 12 → 12
0
(net = strong_buy+buy − sell−strong_sell)
SEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 8-K | 2026-06-09 | 8-K | view · |
| 4 | 2026-05-13 | FORM 4 | view · |
| 4 | 2026-05-13 | FORM 4 | view · |
| 4 | 2026-05-06 | FORM 4 | view · |
| 4 | 2026-05-06 | FORM 4 | view · |
| 4 | 2026-05-06 | FORM 4 | view · |
| 4 | 2026-05-06 | FORM 4 | view · |
| 10-Q | 2026-05-06 | 10-Q | view · |
| 8-K | 2026-05-06 | 8-K | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| DEF 14A | 2026-04-21 | DEF 14A | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 10-K | 2026-02-25 | 10-K | view · |
| 8-K | 2026-02-25 | 8-K | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-02-04 | FORM 4 | view · |
| 4 | 2026-01-07 | FORM 4 | view · |
| 4 | 2026-01-06 | FORM 4 | view · |
| 4 | 2026-01-02 | FORM 4 | view · |
| 4 | 2025-12-17 | FORM 4 | view · |
| 4 | 2025-12-08 | FORM 4 | view · |
| 8-K | 2025-12-08 | 8-K | view · |
| 4 | 2025-12-03 | FORM 4 | view · |
| 4 | 2025-12-03 | FORM 4 | view · |
| 4 | 2025-11-25 | FORM 4 | view · |
| 4 | 2025-11-24 | FORM 4 | view · |
| 4 | 2025-11-21 | FORM 4 | view · |
| 4 | 2025-11-21 | FORM 4 | view · |
| 4 | 2025-11-17 | FORM 4 | view · |
| 4 | 2025-11-17 | FORM 4 | view · |
| 4 | 2025-11-10 | FORM 4 | view · |
| 4 | 2025-11-10 | FORM 4 | view · |
| 4 | 2025-11-05 | FORM 4 | view · |
| 4 | 2025-11-05 | FORM 4 | view · |
| 4 | 2025-11-05 | FORM 4 | view · |
| 4 | 2025-11-05 | FORM 4 | view · |
| 4 | 2025-11-05 | FORM 4 | view · |
| 4 | 2025-10-30 | FORM 4 | view · |
| 10-Q | 2025-10-28 | 10-Q | view · |
| 8-K | 2025-10-28 | 8-K | view · |
| 4 | 2025-10-06 | FORM 4 | view · |
About
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.